Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
GlaxoSmithKline
Modality
Small molecule
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01573819CT.gov A Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278 | — | Completed | — | — | — |
NCT01602900CT.gov Healthy Volunteer Positron Emission Tomography (PET) Brain Occupancy Study of a Phosphodiesterase 4 (PDE4) Inhibitor in Huntington's Disease | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Huntington Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| gsk356278 (this asset) | GlaxoSmithKline | P1 | CCC · 48 |
| Deutetrabenazine | Teva Branded Pharmaceutical Products R&D LLC | P4 | BBB |
| Tetrabenazine | William Ondo, MD | P4 | BBB |
| Tominersen | Hoffmann-La Roche | P3 | BB |
| Latrepirdine | Medivation, Inc. | P3 | BB |
| Pridopidine | Prilenia | P3 | BB |
| MT-5199 | Neurocrine Biosciences | P3 | BB |
| Dalzanemdor | Supernus Pharmaceuticals, Inc. | P3 | BB |
| Cellavita-Hd | Azidus Brasil | P2/3 | BB |
+42 more in the Huntington Disease cohort
Other indications for gsk356278
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Mixed Anxiety And Depressive Disorder | — | P1 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. gsk356278 in Huntington Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/gsk356278-huntington-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →